LITSNasdaqFinance ServicesUS GAAP · USD

Lite Strategy, Inc.

Lite Strategy, Inc. is a U.S.-based pharmaceutical company that has historically developed novel oncology therapies, including voruciclib and zandelisib, through clinical development and partnering. In 2025, it also adopted a Litecoin Treasury Strategy, adding digital asset reserve management to a business that now combines drug development with crypto treasury activities.

Kysy yhtiöstä
Liikevoitto (EBIT)−66,6milj. USD
−281,4 %v/v
Nettotulos−71,2milj. USD
−346,2 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

−100−50050100milj. USD2021: 35 milj. USD2021: EBIT −60 milj. USD20212022: 41 milj. USD2022: EBIT −75 milj. USD20222023: 49 milj. USD2023: EBIT −37 milj. USD20232024: 65 milj. USD2024: EBIT 15 milj. USD20242025: 0,00 milj. USD2025: EBIT −17 milj. USD20252026: EBIT −67 milj. USD2026−67
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Lite Strategy, Inc.

Liiketoiminta

Osuus liikevaihdosta
Oncology drug candidates0 %

Clinical and pre-clinical cancer therapies, including voruciclib and zandelisib.

Drug development and partnering100 %

Development, licensing, and commercialization activities around acquired oncology assets.

Digital asset treasury management0 %

Litecoin holdings and related option-based treasury strategies.

Asiakkaat

The company’s historical customers are pharmaceutical and biotechnology partners, including licensees and commercialization counterparties such as KKC. Its drug development work is aimed at patients with cancers such as AML and other oncology indications, but the company itself monetizes through partnerships, licensing, and development arrangements rather than direct product sales. The newer Litecoin treasury strategy does not create traditional customers; instead, it involves counterparties in digital asset custody, trading, and derivatives markets.

Pharmaceutical licensing partners

Buy or license rights to oncology assets for regional development or commercialization.

Clinical development ecosystem

Clinical sites, investigators, and service providers used to advance drug candidates.

Oncology patients and physicians

End users of the therapies being developed, especially in hematologic cancers.

Digital asset service counterparties

Custodians, asset managers, and option counterparties supporting the Litecoin treasury strategy.

Strategia

The company’s legacy strategy is to build value in oncology assets through clinical development, partnerships, and selective commercialization or out-licensing. In 2025 it added a Litecoin Treasury Strategy, using digital assets and covered call options to diversify reserves and seek incremental liquidity and income. This creates a dual-track model that combines high-risk biotech development with a treasury approach tied to crypto market exposure.

Advance oncology pipelineKeskipitkä aikaväli

Clinical progress is the main path to value creation in the legacy pharmaceutical business.

Monetize through partnershipsKeskipitkä aikaväli

The company has limited internal commercialization scale and relies on external partners to capture value.

Build Litecoin treasury frameworkLyhyt aikaväli

Management is using digital assets to diversify reserves and potentially improve capital efficiency.

Maantiede

Lite Strategy is headquartered in the United States and its employees are all U.S.-based. The company’s historical drug development and licensing activities have been global in scope, including worldwide rights to its current candidates and limited Japanese compassionate-use rights retained by KKC after termination of the commercialization agreement. Its new Litecoin treasury strategy is also global in market reference, but custody and counterparty arrangements are described as primarily U.S.-based.

Riskit

The company faces classic biotech risks: clinical failure, regulatory delays, and dependence on third-party manufacturers and trial infrastructure. It also now carries substantial crypto-specific risks, including Litecoin price volatility, custody/cybersecurity exposure, and potential regulatory reclassification that could affect both the asset and the company’s status. Because the business has no current product revenue, execution risk in both the pipeline and treasury strategy has an outsized effect on liquidity and valuation.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Litecoin price volatility2Regulatory approval delays3Crypto regulatory change4Cybersecurity and custody risk5Contract manufacturing dependence6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    Drug candidates may not show sufficient efficacy or safety in trials, which is common in oncology development.

    KohdistuuVoruciclibZandelisib
  2. Litecoin price volatilityVaikutus: KorkeaTodennäköisyys: Korkea

    Treasury value and any option-related economics depend on a highly volatile digital asset.

    Kohdistuu: LTC holdings

  3. Regulatory approval delaysVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA and other regulators can require extensive data and may delay or deny approval.

    Kohdistuu: oncology pipeline

  4. Crypto regulatory changeVaikutus: KorkeaTodennäköisyys: Kohtalainen

    New rules or reclassification of Litecoin could impair liquidity, ownership, or market value.

    Kohdistuu: digital asset treasury strategy

  5. Cybersecurity and custody riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Digital assets are exposed to theft, hacking, and operational failures at custodians or counterparties.

    Kohdistuu: LTC custody and derivatives counterparties

  6. Contract manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Matala

    The company lacks commercial manufacturing capability and relies on third parties for cGMP supply.

    Kohdistuu: clinical and future commercial supply

Kysy Clarifolta: Lite Strategy, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition under ASC 606

Historical revenue came from a commercialization agreement and was recognized as performance obligations were satisfied.

Vaikutus: Revenue fell to zero after deferred revenue was fully recognized and the agreement terminated.

Impairment of long-lived and intangible assets

Clinical-stage assets require estimates of future cash flows and recoverability.

Vaikutus: Can create large non-cash charges and reduce asset values.

Digital assets and derivative liabilities

LTC holdings and covered call options require fair value measurement and periodic revaluation.

Vaikutus: Can cause earnings and balance-sheet volatility.

Valuation of equity instruments issued for services

The company disclosed new critical estimates tied to equity instruments exchanged for services.

Vaikutus: Affects operating expenses and equity compensation-like charges.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Grayscale Litecoin Trust (LTC)

LTCN · Commodity Contracts Brokers & Dealers

Canton Strategic Holdings, Inc.

CNTN · Finance Services

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Strategy Inc

MSTR · Finance Services

Moleculin Biotech, Inc.

MBRX · Pharmaceutical Preparations

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Päivitetty: 24.9.2026